百令胶囊联合厄贝沙坦片对膜性肾病患者MMP-9, MMP-3和TIMP-1水平的影响

目的:探究百令胶囊联合厄贝沙坦片对膜性肾病患者基质金属蛋白酶-9、3和金属蛋白酶组织抑制物-1影响。方法:收集我院肾内科收治的膜性肾病患者98例,根据随机对照表分为对照组和试验组,每组49例。对照组给予厄贝沙坦片治疗,试验组联合百令胶囊治疗。对比分析两组患者的临床疗效、血清Scr、BUN、UA、Ccr、尿蛋白、MMP-9、MMP-3及TIMP-l水平以及不良反应的发生情况。结果:治疗后,对照组临床总有效率为81.63%,显著低于试验组的95.92%(P0.05)。两组治疗后血清Scr、BUN、UA、MMP-9、MMP-3、TIMP-l水平均显著降低,且试验组显著低于对照组(P0.05),Ccr水平升高,且试验组显著高于对照组(P0.05)。对照组不良反应发生率为10.20%,试验组为6.25%,差异无统计学意义(P0.05)。结论:百令胶囊联合厄贝沙坦片对膜性肾病患者的临床疗效显著,安全性较高,可能与其显著降低MMP-9、MMP-3和TIMP-1水平有关。

Effect of Corbrin and Irbesartan on SerumLevels of MMP- 9, MMP-3 and TIMP-1 of Patients with Membranous Nephropathy

Objective:To investigate the effect of MMP-9, MMP-3 and TIMP-1 by corbrin capsules combined with irbesartan tablets in patients with membranous nephropathy.Methods:98 patients with membranous nephropathy in nephrology department from our hospital were collected and randomly divided into the experiment group and the control group with 49 cases in each group. Patients in the control group were treated by irbesartan tablets, patients in the experiment group were treated on the base of the control group with corbrin capsules. The clinical efficacy, serum Scr, BUN, UA, Ccr, urine protein, MMP-9, MMP-3 and TIMP-l levels and adverse reactions of the two groups were observed and compared before and after treatment.Results:After treatment, the clinical total effective rate of the control group (81.63%) was significantly lower than the experiment group (95.92%) (P< 0.05). The serum Scr, BUN, UA, MMP-9, MMP-3 and TIMP-l levels significantly decreased in two groups after treatment, and the indexes in the experiment group were significantly lower (P<0.05), the Ccr level increased in two groups, and the Ccr level in the experiment group was significantly higher (P<0.05). The adverse reactions rate of the control group was 14.58%, the experiment group was 6.25%, there was no statistically significant difference (P>0.05).Conclusion:Corbrin capsules combine with irbesartan tablets in the treatment of patients with membranous nephropathy is effective with high safety, it can significantly reduce the matrix metalloproteinase-9, 3 and tissue inhibitor of metalloproteinase1 levels.